-
公开(公告)号：US20120122847A1
公开(公告)日：2012-05-17
申请号：US13157195
申请日：2011-06-09
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Zihao Hua , Matthew Martin , Issac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Zihao Hua , Matthew Martin , Issac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502 , A61P35/00 , C07D413/14 , A61K31/5377 , C07D471/04 , A61K31/55
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US07776857B2
公开(公告)日：2010-08-17
申请号：US12080669
申请日：2008-04-03
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： C07D237/30
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20090069297A1
公开(公告)日：2009-03-12
申请号：US12080669
申请日：2008-04-03
申请人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Victor Cee , Holly Deak , Bingfan Du , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Isaac Marx , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502 , C07D237/30 , A61K31/55 , A61P35/00 , C07D403/14
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20100280008A1
公开(公告)日：2010-11-04
申请号：US12828067
申请日：2010-06-30
申请人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Matthew Martin , Hanh Nho Nguyen , Philip Olivieri , Kathleen Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/502 , C07D413/14 , C07D401/14 , C07D401/12 , A61P35/00
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US07981891B2
公开(公告)日：2011-07-19
申请号：US12828067
申请日：2010-06-30
申请人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Hanh Nho Nguyen , Philip Olivieri , Kate Panter , Karina Romero , Laurie Schenkel , Ryan White
发明人： Holly Deak , Stephanie Geuns-Meyer , Brian L. Hodous , Zihao Hua , Mathew Martin , Hanh Nho Nguyen , Philip Olivieri , Kate Panter , Karina Romero , Laurie Schenkel , Ryan White
IPC分类号： A61K31/502
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
摘要翻译： 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。
-
公开(公告)号：US20070054916A1
公开(公告)日：2007-03-08
申请号：US11240590
申请日：2005-09-30
申请人： Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
发明人： Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
IPC分类号： A61K31/525 , A61K31/519 , A61K31/517
CPC分类号： C07D215/38 , C07C205/37 , C07D215/12 , C07D217/12 , C07D217/22 , C07D217/26 , C07D239/26 , C07D239/84 , C07D239/94 , C07D239/95 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译： 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病，包括炎症，癌症和相关病症的化合物。 化合物具有通式I，其中A 1，A 2，A 3，B，R 1， R 2，R 3和R 4在本文中定义。 因此，本发明还包括含有本发明化合物的药物组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号：US08557816B2
公开(公告)日：2013-10-15
申请号：US13157195
申请日：2011-06-09
IPC分类号： A61K31/502
CPC分类号： C07D471/04 , C07D401/12 , C07D401/14 , C07D487/04 , C07D493/04 , C07D495/04
摘要： The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
-
8.发明申请SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE 有权作为β-分泌酶调节剂的螺环四环化合物及其使用方法公开(公告)号：US20110251190A1
公开(公告)日：2011-10-13
申请号：US13047734
申请日：2011-03-14
申请人： Yuan CHENG , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
发明人： Yuan CHENG , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
IPC分类号： A61K31/538 , A61K31/436 , C07D413/14 , C07D417/14 , A61K31/444 , A61P25/00 , C07D513/10 , A61K31/4545 , C07D498/10 , A61K31/497 , A61P25/28 , A61P25/16 , C07D513/20 , A61K31/506
CPC分类号： C07D491/10 , A61K31/42 , A61K31/422 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D221/20 , C07D235/02 , C07D263/08 , C07D295/135 , C07D498/10 , C07D498/20 , C07D513/10 , C09B11/28
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
摘要翻译： 本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默氏病（AD））和其它相关病症的新一类化合物。 在一个实施方案中，化合物具有通式I，其中式I中的A1，A2，A3，A4，A5，A6，R2，R7，X和Y如本文所定义。 本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。 这种病症包括例如阿尔茨海默氏病，认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。 本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。
-
9.发明授权Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use 有权螺四环环化合物作为β-分泌酶调节剂和使用方法公开(公告)号：US08883782B2
公开(公告)日：2014-11-11
申请号：US13047734
申请日：2011-03-14
申请人： Yuan Cheng , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
发明人： Yuan Cheng , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
IPC分类号： A61K31/42 , A61K31/422 , A61K31/506 , A61K31/4439 , A61K31/5377 , C07D221/20 , C07D235/02 , C07D263/08 , C07D295/135 , C07D491/10 , C07D498/10
CPC分类号： C07D491/10 , A61K31/42 , A61K31/422 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D221/20 , C07D235/02 , C07D263/08 , C07D295/135 , C07D498/10 , C07D498/20 , C07D513/10 , C09B11/28
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
摘要翻译： 本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默氏病（AD））和其它相关病症的新一类化合物。 在一个实施方案中，化合物具有通式I，其中式I中的A1，A2，A3，A4，A5，A6，R2，R7，X和Y如本文所定义。 本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。 这种病症包括例如阿尔茨海默氏病，认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。 本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。
-
10.发明授权Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use 有权螺三环环化合物作为β-分泌酶调节剂和使用方法公开(公告)号：US08426447B2
公开(公告)日：2013-04-23
申请号：US12558426
申请日：2009-09-11
申请人： Ryan White , Albert Amegadzie , Marian C. Bryan , Jian Jeffrey Chen , Alan C. Cheng , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Zihao Hua , Jason Brooks Human , Hongbing Huang , Charles Kreiman , Daniel La , Qingyian Liu , Vu Van Ma , Isaac Marx , Vinod F Patel , Wenyuan Qian , Matthew Weiss , Chester Chenguang Yuan
发明人： Ryan White , Albert Amegadzie , Marian C. Bryan , Jian Jeffrey Chen , Alan C. Cheng , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Zihao Hua , Jason Brooks Human , Hongbing Huang , Charles Kreiman , Daniel La , Qingyian Liu , Vu Van Ma , Isaac Marx , Vinod F Patel , Wenyuan Qian , Matthew Weiss , Chester Chenguang Yuan
IPC分类号： A61K31/44 , C07D311/82 , C07D401/00 , C07D413/00
CPC分类号： C07D498/10 , C07D513/10
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
摘要翻译： 本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。 在一个实施方案中，化合物具有通式I，其中式I的A1，A2，A3，A4，A5，A6，T1，T2，W，X，Y和Z如本文所定义。 本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。 这种病症包括例如阿尔茨海默氏病，认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。 本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.077 秒)
